CyFlow™ CD18 Low Endotoxin

CyFlow™ CD18 Low Endotoxin
Target Species: Mouse
Antigen: CD18
Field of Interest: Immunophenotyping, MHC
Clone: M18/2
Regulatory Status: RUO
Alternative Name: b2 integrin
Application: Flow cytometry, Functional assays, Immunohistochemistry, Immunoprecipitation, Western blot
Format/Fluorochrome: Low Endotoxin
Species of Origin: Rat
Clonality: monoclonal
Isotype: IgG2a
Product number: AJ518875

For Research Use Only

$130.00 USD*

Price excludes any applicable taxes plus shipping costs

Concentration 1 mg/mL Quantity 0.1 mg Volume 0.1 mL Immunogen Mouse cytotoxic T... more
CyFlow™ CD18 Low Endotoxin
Concentration1 mg/mL
Quantity0.1 mg
Volume0.1 mL
ImmunogenMouse cytotoxic T cell glycoproteins
Background InformationCD18 (integrin β2 subunit) forms heterodimers with four types of CD11 molecule to constitute leukocyte (β2) integrins: αLβ2 (CD11a/CD18, LFA-1), αMβ2 (CD11b/CD18, Mac-1, CR3), αXβ2 (CD11c/CD18) and αDβ2 (CD11d/CD18). In most cases, the response mediated by the integrin is a composite of the functions of its individual subunits. These integrins are essential for proper leukocyte migration, mediating intercellular contacts.
Storage BufferThe reagent is provided in azide-free phosphate buffered saline (PBS) solution, pH ≈7.4; 0.2 µm filter sterilized. Endotoxin level is less than 0.01 EU/µg of the protein, as determined by the LAL test.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Sanchez-Madrid F, Simon P, Thompson S, Springer TA: Mapping of antigenic and functional epitopes on the alpha‑ and beta‑subunits of two related mouse glycoproteins involved in cell interactions, LFA‑1 and Mac‑1. J·Exp·Med. 1983·Aug·1; 158(2):586‑602. <·PMID:·6193226·> | Zahalka MA, Okon E, Naor D: Blocking lymphoma invasiveness with a monoclonal antibody directed against the beta‑chain of the leukocyte adhesion molecule (CD18). J·Immunol. 1993·May·15; 150(10):4466‑77. <·PMID:·8097756·> | Zahalka MA, Naor D: Beta 2‑integrin dependent aggregate formation between LB T cell lymphoma and spleen cells: assessment of correlation with spleen invasiveness. Int·Immunol. 1994·Jun; 6(6):917‑24. <·PMID:·7522049·> | Avni O, Pur Z, Yefenof E, Baniyash M: Complement receptor 3 of macrophages is associated with galectin‑1‑like protein. J·Immunol. 1998·Jun·15; 160(12):6151‑8. <·PMID:·9637533·> | Abraham C, Miller J: Molecular mechanisms of IL‑2 gene regulation following costimulation through LFA‑1. J·Immunol. 2001·Nov·1; 167(9):5193‑201. <·PMID:·11673532·> | Sakurai E, Taguchi H, Anand A, Ambati BK, Gragoudas ES, Miller JW, Adamis AP, Ambati J: Targeted disruption of the CD18 or ICAM‑1 gene inhibits choroidal neovascularization. Invest·Ophthalmol·Vis·Sci. 2003·Jun; 44(6):2743‑9. <·PMID:·12766082·> | Barlow SC, Langston W, Matthews KM, Chidlow JH Jr, Kevil CG: CD18 deficiency protects against multiple low‑dose streptozotocin‑induced diabetes. Am·J·Pathol. 2004·Dec; 165(6):1849‑52. <·PMID:·15579429·> | Watts GM, Beurskens FJ, Martin-Padura I, Ballantyne CM, Klickstein LB, Brenner MB, Lee DM: Manifestations of inflammatory arthritis are critically dependent on LFA‑1. J·Immunol. 2005·Mar·15; 174(6):3668‑75. <·PMID:·15749905·> | Varga G, Balkow S, Wild MK, Stadtbaeumer A, Krummen M, Rothoeft T, Higuchi T, Beissert S, Wethmar K, Scharffetter-Kochanek K, Vestweber D, Grabbe S: Active MAC‑1 (CD11b/CD18) on DCs inhibits full T‑cell activation. Blood. 2007·Jan·15; 109(2):661‑9. <·PMID:·17003381·> | Cullere X, Lauterbach M, Tsuboi N, Mayadas TN: Neutrophil‑selective CD18 silencing using RNA interference in vivo. Blood. 2008·Apr·1; 111(7):3591‑8. <·PMID:·18216298·>

Article successfully added.